Funding for this research was provided by:
Takeda Pharmaceutical Company (04-078-0067)
Keio University (04-013-0188)
Received: 29 April 2020
Accepted: 15 June 2020
First Online: 22 June 2020
Ethics approval and consent to participate
: Ethics approval was obtained from the Institutional Review Board of Keio University School of Medicine (IRB No. 20110258). Consent to participate was obtained from all subjects in the current study before the blood specimen was collected.
: Not applicable.
: YK, YO, MTaki and RK are employed by Takeda Pharmaceutical Company Limited. S.T. was employed by Takeda Pharmaceutical Company Limited. KS has received research grants from Eisai, Bristol-Myers Squibb, Kissei Pharmaceutical and Daiichi Sankyo; speaking fees from Abbie Japan, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Fuji Film Limited, Janssen Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Shionogi, Takeda Pharmaceutical and UCB Japan; and consulting fees from Abbie and Pfizer Japan. AY has received speaking fees from Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, Maruho and Novartis, and consulting fees from GSK Japan. TT has received research grants from Astellas Pharma Inc., Bristol-Myers KK, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., AbbVie GK, Asahikasei Pharma Corp, Mitsubishi Tanabe Pharma Co, Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co. Ltd., Eisai Co. Ltd., AYUMI Pharmaceutical Corporation and Nipponkayaku Co. Ltd.; speaking fees from AbbVie GK, Bristol-Myers KK, Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co, Pfizer Japan Inc., Astellas Pharma Inc. and Diaichi Sankyo Co. Ltd.; and consultant fees from Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, Mitsubishi Tanabe Pharma Co, Abbivie GK, Nipponkayaku Co. Ltd., Janssen Pharmaceutical KK, Astellas Pharma Inc. and Taiho Pharmaceutical Co. Ltd. JI and MT declare no potential conflict of interest.